SequelSEC

Bone Biologics Corp BBLG

Orthopedic, Prosthetic & Surgical Appliances & Supplies · CIK 0001419554 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.07B
Fiscal year ended 2020-12-31
Operating income
-$825.01K
Fiscal year ended 2020-12-31
Free cash flow
Unavailable
Fiscal year ended 2020-12-31

Bone Biologics Corp (BBLG) reported revenue of $1.07B and net income of -$1.82M for the fiscal year ended 2020-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Bone Biologics Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Orthopedic, Prosthetic & Surgical Appliances & Supplies.

Income

Bone Biologics Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312016-12-31
Revenue$1.07B$1.07B$1.07B
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$825.01K-$2.45M-$20.41M
Net income-$1.82M-$3.42M-$25.88M
Research & development$340.67K$1.10M$10.17M
Weighted-average diluted sharesUnavailableUnavailableUnavailable
Pretax income-$1.82M-$3.42M-$25.88M
Income tax expense$1.60K$1.60K$2.24K
Diluted EPSUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$484.34K$1.35M$5.65M
Selling & marketingUnavailableUnavailableUnavailable

Balance

Bone Biologics Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312016-12-31
Cash & equivalentsUnavailable$24.14K$620.38K
Total assets$0$30.83K$701.14K
Current assetsUnavailable$30.83K$700.90K
Total liabilities$13.69M$11.90M$9.06M
Current liabilities$13.69M$578.45K$1.50M
Total equity incl. NCI-$13.69M-$11.87M-$8.36M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$465.40K$42.88K$226.52K

Cash flow

Bone Biologics Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312016-12-31
Operating cash flow-$426.93K-$3.25M-$7.33M
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailable
Financing cash flow$402.79K$2.32M$6.83M
Net change in cash-$24.14K-$931.23K-$494.73K
Stock-based compensationUnavailable$49.69K$4.14M
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

Bone Biologics Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312016-12-31
Free cash flowUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratioUnavailableUnavailable0.47x
Revenue YoY growth0.0%UnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BBLG in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

ALGN APT AVR CDRE COCH ENOV ESTA EW FEED INGN ISRG LAKE

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.